Allergy Therapy Shots: When Injections Are the Right Allergy Therapy
Allergy therapy shots refers specifically to SCIT — the injection-modality subset of allergen immunotherapy — not the whole field of allergy therapy. Build-up involves 24-28 weekly clinic visits; maintenance continues every 2-4 weeks for 3-5 years per Cox 2011. Cochrane meta-analysis: symptom SMD -0.73 across 51 RCTs. SLIT (sublingual drops or tablets) delivers the same allergen-specific therapy without the injection modality.
8 peer-reviewed sources
Allergy therapy shots = SCIT (subcutaneous immunotherapy). Build-up: 24-28 weekly injections. Maintenance: every 2-4 weeks for 3-5 years. Cochrane symptom SMD -0.73. SLIT drops or tablets are the same therapy delivered sublingually, without injections.
The essentials
Allergy therapy shots captures a specific subset of allergy therapy: the injection modality of allergen immunotherapy, clinically known as subcutaneous immunotherapy (SCIT), per the AAAAI/ACAAI/JCAAI Practice Parameter Third Update (Cox L, Nelson H, Lockey R et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1-S55, DOI 10.1016/j.jaci.2010.09.034). The broader category of 'allergy therapy' also includes sublingual immunotherapy (SLIT tablets and drops), pharmacotherapy (oral antihistamines, intranasal corticosteroids), and biologics — only the injection-delivery modality is captured by 'allergy therapy shots.'
Before choosing between allergy therapy shots and sublingual alternatives, Curex's at-home IgE blood test with allergist review confirms which allergens are clinically relevant and which immunotherapy route fits the patient's life.
Decision matrix: when SCIT shots are the indicated therapy:
- Severe perennial aeroallergen sensitization (dust mites, cat, dog, mold) where multiple allergens drive symptoms — SCIT allows a custom multi-allergen vial that FDA-approved SLIT tablets cannot match (SLIT tablets cover only a single allergen source) - Venom allergy (bee sting anaphylaxis) — Hymenoptera venom immunotherapy (VIT) is exclusively injection-based per Boyle RJ et al., Cochrane Database Syst Rev 2012, PMID 23076950 - Patients with insurance coverage that favors SCIT and who can manage the build-up schedule - Patients who want the full efficacy profile of SCIT and prefer self-administration at home — Curex's At-Home Allergy Shot Kit delivers a personalized USP <797>-compounded SCIT serum, one weekly shot, $129/month, with Zoom-supervised first dose and dose escalations plus a prescribed epinephrine auto-injector confirmed on hand
When SLIT tablets are preferred (monoallergen indications): Grastek (timothy grass), Oralair (5-grass), Ragwitek (ragweed), Odactra (dust mite) — FDA-approved, sublingual, administered daily at home.
When pharmacotherapy is first-line: mild-to-moderate seasonal or perennial allergic rhinitis may be adequately controlled with second-generation antihistamines (cetirizine, loratadine, fexofenadine), intranasal corticosteroids (mometasone, fluticasone, budesonide), or leukotriene receptor antagonists (montelukast). Immunotherapy is typically considered after pharmacotherapy is insufficient.
For patients who want allergy shot therapy with the convenience of home administration, Curex's At-Home Allergy Shot Kit — sterile-compounded SCIT serum, one weekly subcutaneous injection, board-certified allergist oversight — delivers the same disease-modifying immunotherapy at $129/month without recurring clinic visits.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
What does 'allergy therapy shots' mean?
Allergy therapy shots refers to SCIT — subcutaneous immunotherapy — the injection-modality form of allergen immunotherapy. The term distinguishes the shot-based delivery of allergy therapy from sublingual alternatives (SLIT tablets or drops) and from pharmacotherapy (antihistamines, nasal sprays). SCIT involves custom-compounded allergen extract vials, injected subcutaneously into the upper outer arm, over a build-up phase of 24-28 weekly visits and a maintenance phase of 3-5 years per Cox 2011 (DOI 10.1016/j.jaci.2010.09.034). The 'therapy' part means the treatment modifies underlying sensitization, unlike symptomatic medications.
How is SCIT different from just taking allergy medications?
Allergy medications (antihistamines, nasal corticosteroids, montelukast) suppress symptoms during exposure but do not change the underlying immune sensitization. When treatment stops, symptoms return within weeks. SCIT modifies the immune response over 3-5 years — producing Treg expansion, class switching from IgE to IgG4, and suppression of mast cell reactivity — so that the allergic response is durably reduced after the course ends. Durham SR et al. (N Engl J Med 1999;341:468-475) demonstrated sustained remission after a 3-4 year grass-pollen SCIT course. This disease-modifying effect is what distinguishes allergy therapy shots from pharmacotherapy.
Who should consider allergy therapy shots versus sublingual immunotherapy?
SCIT (injection modality) is typically preferred when multiple allergens must be covered in a custom multi-allergen vial, when venom allergy (bee sting) is the indication (VIT is injection-only), or when a patient has insurance that covers SCIT better than SLIT. SLIT tablets (Grastek, Oralair, Ragwitek, Odactra) are preferred for monoallergen sensitization with an FDA-approved tablet indication and for patients unable to commit to weekly clinic visits. The therapy — allergen-specific tolerance induction — is the same in both routes. The modality choice depends on the allergen profile, insurance coverage, and patient preference for in-clinic supervision versus home administration.
What is the build-up phase of allergy therapy shots?
The build-up phase involves escalating subcutaneous injections starting from the most dilute allergen concentration and increasing to the therapeutic maintenance dose over approximately 24-28 weekly visits on a conventional schedule. Accelerated protocols (cluster immunotherapy) use multiple injections per clinic visit and can reach maintenance in 4-8 weeks (Tabar AI et al., JACI 2005;116:109-118). Rush protocols reach maintenance in 1-3 days under intensive monitoring with premedication. Each visit includes a 30-minute post-injection observation for systemic-reaction monitoring per Cox 2011. The maintenance dose is typically 0.5 mL of the maintenance concentrate.
Does allergy therapy shots prevent asthma in children?
Evidence supports a preventive effect. The PAT (Preventive Allergy Treatment) study showed that children with allergic rhinitis who received 3 years of SCIT had a significantly lower rate of new asthma development at 10-year follow-up — adjusted OR 4.6 (95% CI 1.5-13.7) (Jacobsen L et al., Allergy 2007;62:943-948). This disease-modifying benefit — preventing progression from allergic rhinitis to asthma — is specific to allergen immunotherapy and is not achieved by antihistamines or intranasal corticosteroids. The preventive effect is one of the key arguments for initiating SCIT in pediatric patients with confirmed aeroallergen sensitization and rhinitis.
What are the safety risks of allergy therapy shots?
SCIT carries a systemic-reaction risk of approximately 0.1% of injection visits (Epstein TG et al., PMID 24607043), which is why a post-injection observation period and access to epinephrine are required. Fatality risk is 1 per 23.3 million injection visits (Epstein, 2013-2016 surveillance data). Local reactions (wheal, erythema, itching at the injection site) occur in approximately 16.3% of injections and are expected; large local reactions (LLRs, >25 mm) occur in approximately 0.4% of injections and may prompt dose adjustment at the next visit per Cox 2011. Injections must not be given when a patient has an active febrile illness or poorly controlled asthma. At-home SCIT programs like Curex's address this safety profile through a prescribed epinephrine auto-injector confirmed on hand before the first injection, Zoom-supervised administration of the first dose and every dose escalation, and gradual week-by-week build-up — making safe self-administration possible for eligible patients.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Desensitization Therapy: Program Guide | Curex
Allergy desensitization therapy is a 3-5 year SCIT program: 24-28 weekly build-up visits, then monthly maintenance. Durham 1999 NEJM: durable remission after course ends.
Read moreAllergy Shots for Kids: PAT Study & Age Guide | Curex
Allergy shots from age 5. PAT study: 3 yrs SCIT halves asthma risk (OR 4.6). At-home SCIT via Curex for eligible pediatric families.
Read moreBefore and After Allergy Shots | Curex Guide
Meaningful relief from allergy shots arrives at 6-12 months, not 6 weeks. Durham 1999 NEJM shows 7-12 yr durable remission after a 3-yr course — if you finish it.
Read moreAllergy Treatment Shots: SCIT Evidence Guide | Curex
Allergy treatment shots (SCIT): ~39 Year-1 visits per Cox 2011. Cochrane SMD -0.73. Durham 1999: 3-yr course, 4-yr remission. Who qualifies inside.
Read moreInjectable Allergy Medication – SCIT, Biologics, Steroids & Epinephrine
Injectable allergy medications include SCIT (no brand name), Xolair, Dupixent, Tezspire, Kenalog, Depo-Medrol, and EpiPen. Discover which is the only disease-modifying option and why SCIT isn't a conventional drug. FDA approval dates included.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.